Europe Rapid Diagnostic Tests Rdt Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 12.05 Billion |
 Market Size (Forecast Year) |
USD 21.64 Billion |
 CAGR |
% |
| Major Markets Players |
Europe Rapid Diagnostic Test (RDT) Market, By Product Type (Consumables and Kits, Instruments, and Others), Mode (Professional and Over-The-Counter [OTC]), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology, and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum, and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, and Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2031.
Europe Rapid Diagnostic Tests (RDT) Market Analysis and Insights
Rise in rapid diagnostic tests for the diagnosis of chronic infectious diseases such as Human Immuno Deficiency Virus (HIV), malaria, and other diseases are driving the market growth. Lack of skilled professionals has caused many accidents and errors during diagnostics is expected to challenge market growth.
Data Bridge Market Research analyses that the Europe Rapid Diagnostic Tests (RDT) market is expected to reach USD 21.64 billion by 2031 from USD 12.05 billion in 2023, growing with a healthy CAGR of 8.2% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016–2021) |
|
Quantitative Units |
Revenue in USD Billion |
|
Segments Covered |
Product Type (Consumables and Kits, Instruments, and Others), Mode (Professional and Over-The-Counter [OTC]), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology, and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum, and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, and Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe |
|
Market Players Covered |
Abbott, Danaher, Cellex, Fujirebio, AdvaCare Pharma, ACCESS BIO, Cardinal Health, Bio-Rad Laboratories, Inc., Cepheid, BD, F. Hoffmann-La Roche Ltd, bioMérieux SA, InBios International, Inc, Luminex Corporation, Gnomegen LLC, QIAGEN, Quidel Corporation, , Inc., Sysmex Corporation, Cardinal Health, Siemens Healthcare Gmbh, MEGACOR DIAGNOSTIK, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics, werfen, Nova Biomedical, and Trinity Biotech among others |
Market Definition
Rapid diagnostic tests are preferred over standard diagnostic tests since they can boost the aetiologic analysis of infections in several situations (for instance, sepsis, respiratory tract infections, and meningitis). The elucidation of the currently available rapid diagnostic tests is not always upfront, and therefore, they cannot yet replace conventional tests. There are three types of rapid diagnostic tests. The rapid immunoassay test strips or cassettes are used to measure the concentration of a chemical. Test strips are most often used to test the pH level of a liquid in a sample, but some types of test strips serve other purposes, such as detecting the presence of a contaminant.
Europe Rapid Diagnostic Tests (RDT) Market Dynamics
Drivers
- Increase in the Incidence of Chronic Diseases
The driving factors responsible for the growth of the market is the increase in the incidence of chronic diseases, the rise in the geriatric population, technological developments in rapid diagnostic tests, and the rise in product launches. However, the factors that are expected to restrain the market are the rise in the cost of rapid diagnostics, product recalls faced in rapid diagnostic tests, and lack of awareness about the use of rapid diagnostics. Moreover, the strategic initiatives by market players and the rise in healthcare expenditure bolster the market growth.
- Rise in Geriatric Population of the Infectious Diseases
The aging population worldwide is facing an increased risk of chronic and malignant diseases due to a variety of factors, including changes in the immune system, lifestyle, and exposure to environmental factors over time. The susceptibility of the geriatric population to such health challenges highlights the importance of effective and efficient diagnostic tools to identify and manage these conditions. One notable aspect in this context is the prevalence of non-specific antibodies in the elderly, making the detection of specific diseases more challenging.
Opportunity
- Strategic Initiation and Product Launches by Market Players
The market is experiencing a notable trend marked by a rising initiation of new products and launches. This surge in innovation underscores the dynamic nature of the diagnostic landscape, with companies actively introducing novel solutions to address evolving healthcare needs. The growing demand for accurate and rapid diagnostic tools, particularly in the context of an aging population, has stimulated increased investment in research and development.
Restraints/Challenges
- High Cost Associated with the Rapid Diagnostic Kits
The rise in the cost of the rapid diagnostic kit due to robust research and effectiveness. However, the price of the material used and the developments incurred in the therapeutics and services would increase the number of manufacturing units and more workforce and human resources required to diagnose and screen pathogen viability.
The rapid diagnostic development cost is expensive, it requires a proper protocol procurement strategy. However, specialty clinics and diagnostic laboratories face hindrances in purchasing testing devices due to low economic financials, which would limit the sales of test kits and their accessories.
- Stringent Regulations for Market Approval
The regulations are provided for all aspects of the rapid diagnostics tests, such as In-vitro and molecular diagnostics. These rules and regulations are required for market approval to ensure the security and safety of the patients.
Achieving these regulatory approvals for legal formality can entail significant financial expenditure, which could take months or years to complete. If these limitations are not known or taken into account, the probability of success in a highly competitive market can be significantly exposed by delays, which is expected to challenge market growth.
Recent Developments
- In May 2023, F. HOFFMANN-LA ROCHE LTD officially announced the acquisition of Stratos Genomics. This acquisition led to the development of DNA-based sequencing for diagnostics use. This enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company
- In April 2023, In July, bioMérieux SA’s BIOFIRE Respiratory Panel 2.1 plus tests for 23 pathogens, including SARS-CoV-,2 infection, responsible for respiratory tract infections is commercially available for use around the world and helps in the early diagnosis of respiratory infections. This development assisted the company in generating more revenue
Europe Rapid Diagnostic Tests (RDT) Market Scope
The Europe Rapid Diagnostic Tests (RDT) market is categorized into eleven notable segments based on product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables and Kits
- Others
On the basis of product type, the market is segmented into consumables and kits, instruments, and others.
Mode
- Over-The-Counter [OTC]
- Professional
On the basis of mode, the market is segmented into professional and Over-The-Counter [OTC].
Technology
- PCR-Based
- Flow-Through Assays
- Lateral Flow Immunochromatographic Assays
- Microfluidics
- Substrate Technology
- Agglutination Assay
- Others
On the basis of technology, the market is segmented into PCR-based, flow-through assays, lateral flow immunochromatographic assays, agglutination assay, microfluidics, substrate technology, and others.
Modality
- Laboratory Based Test
- Non-Laboratory Based Test
On the basis of modality, the market is segmented into laboratory based test and non-laboratory based test.
Age Group
- Pediatric
- Adult
On the basis of age group, the market is segmented into adult and pediatric.
Test Type
- Determining Confirmation
- Serological Testing
- Viral Sequencing
On the basis of test type, the market is segmented into determining confirmation, serological testing, and viral sequencing.
Approach
- Molecular Diagnostic
- In-Vitro Diagnostic
On the basis of approach, the market is segmented into in-vitro diagnostic and molecular diagnostic.
Specimen
- Swab
- Blood
- Urine
- Saliva
- Sputum
- Others
On the basis of specimen, the market is segmented into swab, blood, urine, saliva, sputum, and others.
Application
- Infectious Disease Testing
- Cardiology Testing
- Oncology Testing
- Pregnancy & Fertility Testing
- Toxicology Testing
- Drugs-of-Abuse Testing
- Cardiometabolic Testing
- Glucose Monitoring
- Others
On the basis of application, the market is segmented into infectious disease testing, glucose monitoring, cardiology testing, oncology testing, cardiometabolic testing, drugs-of-abuse testing, pregnancy & fertility testing, toxicology testing, and others.
End User
- Hospital & Clinic
- Diagnostic Laboratory
- Home Care Setting
- Research and Academic Institutes
- Others
On the basis of end user, the market is segmented into hospital & clinic, diagnostic laboratory, home care setting, research and academic institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Regional Analysis: Europe Rapid Diagnostic Tests (RDT) Market
The Europe Rapid Diagnostic Tests (RDT) market is analyzed and market size information is provided product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel.
The countries covered in the Europe Rapid Diagnostic Tests (RDT) market report are the Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and rest of Europe.
Germany is expected to dominate in the market due to the presence of major market players and increased technological advancements of Europe rapid diagnostic test in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Europe Rapid Diagnostic Tests (RDT) Market: Competitive Landscape and Share Analysis
Europe Rapid Diagnostic Tests (RDT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Europe rapid diagnostic test market.
The major companies providing the Europe Rapid Diagnostic Tests (RDT) market are Abbott, Danaher, Cellex, Fujirebio, Pharma, Access Bio, Cardinal Health, Bio-Rad Laboratories, Inc., BD, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX SA, InBios International, Inc, Luminex Corporation. A DiaSorin Company, Gnomegen LLC, QIAGEN, Quidel Corporation, Sysmex Europe Gmbh (A Subsidiary of Sysmex Corporation), Cardinal Health, Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG), MEGACOR DIAGNOSTIK GMBH, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics, werfen, Nova Biomedical, and Trinity Biotech among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET APPLICATION COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASE IN INCIDENCE OF CHRONIC DISEASES
5.1.2 RISE IN GERIATRIC POPULATION OF THE INFECTIOUS DISEASES
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN RAPID DIAGNOSTIC TESTING
5.1.4 GOVERNMENT INITIATIVES FOR DIAGNOSIS OF INFECTIOUS DISEASES
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH THE RAPID DIAGNOSTIC KITS
5.2.2 PRODUCT RECALLS IN RAPID DIAGNOSTIC TESTS
5.2.3 LACK OF AWARENESS ABOUT RAPID DIAGNOSTIC TESTING OF THE DISEASES
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATION AND PRODUCT LAUNCHES BY MARKET PLAYERS
5.3.2 RISE IN GOVERNMENT SUPPORT AND FUNDING FOR RAPID DIAGNOSTIC TEST
5.3.3 INCREASING AWARENESS ABOUT THE PROMPT AND EFFICIENT DIAGNOSIS
4.1 CHALLENGES
5.3.4 STRINGENT REGULATORY FOR MARKET APPROVAL
5.3.5 LACK OF TRAINING AND EXPERTISE IN THE DIAGNOSTIC CENTRES
6 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 CONSUMABLES AND KITS
6.2.1 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
6.2.2 IMMUNOCHROMATOGRAPHIC ASSAY
6.2.2.1 ANTIBODY TESTS
6.2.2.1.1 TOTAL ANTIBODY ELISA KIT
6.2.2.1.2 IGM/IGG RAPID DIAGNOSTIC TEST
6.2.2.1.3 IGG ELISA KIT
6.2.2.1.4 IGM ELISA KIT
6.2.2.1.5 NEUTRALIZING ANTIBODY ELISA KIT
6.2.3 ANTIGEN ELISA KITS
6.2.4 SPECIMEN COLLECTION KIT
6.3 RT-PCR ASSAY KITS
6.3.1 REVERSE TRANSCRIPTION PCR (RT-PCR)
6.3.2 QUANTITATIVE REVERSE TRANSCRIPTION PCR (RT-QPCR)
6.3.3 OTHERS
6.4 INSTRUMENTS
6.4.1 PORTABLE
6.4.2 BENCHTOP
6.4.3 FIXED
6.5 OTHERS
7 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE
7.1 OVERVIEW
7.2 PROFESSIONAL
7.3 OVER-THE-COUNTER [OTC]
8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 PCR-BASED
8.3 FLOW-THROUGH ASSAYS
8.4 LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAYS
8.5 AGGLUTINATION ASSAY
8.6 MICROFLUIDICS
8.6.1 PAPER-BASED MICROFLUDICS
8.6.2 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS)
8.6.3 OTHERS
8.7 SUBSTRATE TECHNOLOGY
8.8 OTHERS
9 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY
9.1 OVERVIEW
9.2 LABORATORY BASED TEST
9.3 NON-LABORATORY BASED TEST
10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 PEDIATRIC
11 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE
11.1 OVERVIEW
11.2 DETERMINING CONFIRMATION
11.2.1 RT-PCR ASSAY KITS
11.2.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.2.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.2.4 OTHERS
11.3 SEROLOGICAL TESTING
11.3.1 RT-PCR ASSAY KITS
11.3.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.3.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.3.4 OTHERS
11.4 VIRAL SEQUENCING
11.4.1 RT-PCR ASSAY KITS
11.4.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.4.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.4.4 OTHERS
12 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH
12.1 OVERVIEW
12.2 IN-VITRO DIAGNOSTIC
12.3 MOLECULAR DIAGNOSTIC
13 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN
13.1 OVERVIEW
13.2 SWAB
13.3 BLOOD
13.4 URINE
13.5 SALIVA
13.6 SPUTUM
13.7 OTHERS
14 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 INFECTIOUS DISEASE TESTING
14.2.1 VIRUS
14.2.2 BACTERIA
14.2.3 OTHERS
14.3 GLUCOSE MONITORING
14.4 CARDIOLOGY TESTING
14.5 ONCOLOGY TESTING
14.5.1 LUNG CANCER
14.5.2 BREAST CANCER
14.5.3 BLOOD CANCER
14.5.4 OTHERS
14.6 CARDIOMETABOLIC TESTING
14.7 DRUGS-OF-ABUSE TESTING
14.8 PREGNANCY & FERTILITY TESTING
14.9 TOXICOLOGY TESTING
14.1 OTHERS
15 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL & CLINIC
15.3 DIAGNOSTIC LABORATORY
15.4 HOME CARE SETTING
15.5 RESEARCH AND ACADEMIC INSTITUTES
15.6 OTHERS
16 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 EUROPE BY COUNTRY
17.1 OVERVIEW
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 NETHERLANDS
17.1.10 SWITZERLAND
17.1.11 REST OF EUROPE
18 EUROPE RAPID DIAGNOSTICS TESTS (RDT) MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ABBOTT
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 F. HOFFMANN-LA ROCHE LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 PTS DIAGNOSTICS
20.4.1 COMPANY SNAPSHOT
20.4.2 PRODUCT PORTFOLIO
20.4.3 RECENT DEVELOPMENTS
20.5 CARDINAL HEALTH
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ACCESS BIO
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 BIOMÉRIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 BIO-RAD LABORATORIES, INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 CELLEX
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 DANAHER
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 FUJIREBIO (A SUBSIDIARY OF H.U. GROUP)
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 GNOMEGAN LLC
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 INBIOS INTERNATIONAL, INC
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 LUMINEX CORPORATION, A DIASORIN COMPANY
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 MEGAKOR DIAGNOSTIK GMBH
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
20.17 NOVA BIOMEDICAL
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 PERKIN ELMER INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 QIAGEN
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 QUIDEL CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
20.21 SEKISUI DIAGNOSTICS
20.21.1 COMPANY SNAPSHOT
20.21.2 PRODUCT PORTFOLIO
20.21.3 RECENT DEVELOPMENTS
20.22 SYSMEX EUROPE GMBH (A SUBSIDIARY OF SYSMEX CORPORATION)
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENTS
20.23 TRINITY BIOTECH
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENT
20.24 WERFEN
20.24.1 COMPANY SNAPSHOT
20.24.2 PRODUCT PORTFOLIO
20.24.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 EUROPE CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 3 EUROPE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 EUROPE ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 5 EUROPE RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 6 EUROPE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 9 EUROPE MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 11 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 12 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 13 EUROPE DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 15 EUROPE VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 17 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 18 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 19 EUROPE INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 20 EUROPE ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 22 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 24 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 GERMANY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 26 GERMANY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 27 GERMANY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 28 GERMANY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 29 GERMANY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 31 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 32 GERMANY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 33 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 34 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 35 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 36 GERMANY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 37 GERMANY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 38 GERMANY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 39 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 40 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 41 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 42 GERMANY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 43 GERMANY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 44 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 45 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 47 FRANCE CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 48 FRANCE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 49 FRANCE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 50 FRANCE RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 51 FRANCE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 FRANCE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 53 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 54 FRANCE MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 55 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 56 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 57 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 58 FRANCE DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 59 FRANCE SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 60 FRANCE VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 61 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 62 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 63 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 64 FRANCE INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 65 FRANCE ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 66 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 67 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.K. CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.K. IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.K. ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.K. RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.K. INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 75 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 76 U.K. MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 77 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 78 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 79 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.K. DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.K. SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.K. VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 83 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 84 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 85 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 U.K. INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 87 U.K. ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 88 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 ITALY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 92 ITALY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 93 ITALY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 ITALY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 95 ITALY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 96 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 97 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 ITALY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 99 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 100 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 101 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 102 ITALY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 103 ITALY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 104 ITALY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 105 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 106 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 107 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 108 ITALY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 109 ITALY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 112 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 113 SPAIN CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 SPAIN IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 SPAIN ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 SPAIN RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 SPAIN INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 119 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 120 SPAIN MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 121 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 122 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 123 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 124 SPAIN DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 125 SPAIN SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 126 SPAIN VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 127 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 128 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 129 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 130 SPAIN INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 131 SPAIN ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 132 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 133 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 134 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 RUSSIA IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 RUSSIA ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 RUSSIA RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 RUSSIA INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 140 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 141 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 142 RUSSIA MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 143 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 144 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 145 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 146 RUSSIA DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 147 RUSSIA SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 148 RUSSIA VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 149 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 150 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 151 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 152 RUSSIA INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 153 RUSSIA ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 154 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 155 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 156 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 157 TURKEY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 158 TURKEY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 TURKEY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 160 TURKEY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 161 TURKEY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 162 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 163 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 164 TURKEY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 165 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 166 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 167 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 168 TURKEY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 169 TURKEY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 170 TURKEY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 171 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 172 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 173 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 174 TURKEY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 175 TURKEY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 176 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 178 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 179 BELGIUM CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 180 BELGIUM IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 181 BELGIUM ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 182 BELGIUM RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 183 BELGIUM INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 184 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 185 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 186 BELGIUM MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 187 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 188 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 189 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 190 BELGIUM DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 191 BELGIUM SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 192 BELGIUM VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 193 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROCH, 2022-2031 (USD MILLION)
TABLE 194 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 195 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 196 BELGIUM INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 BELGIUM ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 198 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 201 NETHERLANDS CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 202 NETHERLANDS IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 203 NETHERLANDS ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 204 NETHERLANDS RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 205 NETHERLANDS INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 206 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 207 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 208 NETHERLANDS MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 209 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 210 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 211 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 212 NETHERLANDS DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 213 NETHERLANDS SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 214 NETHERLANDS VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 215 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROCH, 2022-2031 (USD MILLION)
TABLE 216 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 217 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 218 NETHERLANDS INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 219 NETHERLANDS ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 220 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 221 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 222 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 223 SWITZERLAND CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 224 SWITZERLAND IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 225 SWITZERLAND ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 226 SWITZERLAND RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 227 SWITZERLAND INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 228 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 229 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 230 SWITZERLAND MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 231 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 232 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 233 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 234 SWITZERLAND DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 235 SWITZERLAND SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 236 SWITZERLAND VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 237 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 238 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 239 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 240 SWITZERLAND INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 241 SWITZERLAND ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 242 SWITZERLAND ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 243 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 244 REST OF EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
FIGURE 2 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: APPLICATION COVERAGE GRID
FIGURE 10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
FIGURE 11 THE INCREASED BURDEN OF INFECTIOUS DISEASES, RISE IN AWARENESS OF RAPID DIAGNOSTIC TESTS, AND RISE IN PRODUCT LAUNCHES ARE DRIVING THE GROWTH OF THE EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET FROM 2024 TO 2031
FIGURE 12 CONSUMABLES AND KITS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET FROM 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET
FIGURE 14 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, 2023
FIGURE 15 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 16 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 17 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, 2023
FIGURE 19 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, CAGR (2024-2031)
FIGURE 21 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, LIFELINE CURVE
FIGURE 22 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, 2023
FIGURE 23 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 24 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, CAGR (2024-2031)
FIGURE 25 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, 2023
FIGURE 27 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, CAGR (2024-2031)
FIGURE 29 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 30 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, 2023
FIGURE 31 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 32 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 33 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 34 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, 2023
FIGURE 35 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 38 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, 2023
FIGURE 39 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, 2024-2031 (USD MILLION)
FIGURE 40 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, CAGR (2024-2031)
FIGURE 41 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, LIFELINE CURVE
FIGURE 42 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, 2023
FIGURE 43 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, CAGR (2024-2031)
FIGURE 45 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, LIFELINE CURVE
FIGURE 46 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, 2023
FIGURE 47 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 48 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 49 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 50 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, 2023
FIGURE 51 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 53 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 54 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 55 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 56 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 57 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 58 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SNAPSHOT (2023)
FIGURE 59 EUROPE RAPID DIAGNOSTICS TESTS (RDT) MARKET: COMPANY SHARE 2023 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
